Similar companies
Income Statement (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Operating expense | 7.2M | 34.4% |
| Net Income | -7.6M | 32.2% |
| EBITDA | -6.5M | 35.3% |
Balance Sheet (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Total Assets | 25M | 30.6% |
| Total Liabilities | 1.1M | 97.2% |
| Shares Outstanding | 7M | 8.1% |
Cash Flow (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Cash from operations | -11M | 40.6% |
| Cash from investing | 1,000 | 106.3% |
| Cash from financing | 30,000 | 101.2% |
EPS
Financial Highlights for Kala Pharmaceuticals in Q3 '25
Operating Expenses for this period were 7.2M, showing a -34.4% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -7.6M, showing a 32.2% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -6.5M, showing a 35.3% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
The company's performance remained stable this quarter with no significant positive or negative changes in the key financial metrics.
